• Summary of FDA Advertising and Promotion Enforcement Activities
  • November 2, 2012 | Authors: Scott Cunningham; Scott D. Danzis; Michael S. Labson; Erika Lietzan; Julia F. Post
  • Law Firm: Covington & Burling LLP - Washington Office
  • This e-alert is part of a series of monthly e-alerts summarizing publicly-available FDA enforcement letters (i.e., warning letters and untitled letters) relating to the advertising and promotion of drugs, biologics, and medical devices. In September 2012, FDA’s Office of Prescription Drug Promotion (OPDP) posted the following enforcement letters on its website: